Navigation Links
Synvista Therapeutics Posts Letter to Stockholders on Web Site
Date:9/17/2008

having successfully directed development and registration programs in various therapeutic areas, including cardiovascular and metabolic diseases, dermatology, gastroenterology and immunology.

We are very excited about the role Synvista has to play in fulfilling important, unmet medical needs in diabetic and other patients as we advance our pipeline through development and into commercialization.

Thank you for your continued interest in Synvista. I look forward to keeping you apprised of our progress.

Sincerely,

Noah Berkowitz, M.D., Ph.D.

President and Chief Executive Officer

September 2008

About Synvista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing diagnostics and drugs to diagnose, treat and prevent cardiovascular disease in people with diabetes. The Company has developed a clinical diagnostic test for Hp2-2 Diabetes. The genetic or protein form of this test can be used to identify diabetic patients at high risk for cardiovascular complications. These patients may benefit from a particular formulation of vitamin E. The Company is also developing a kit to measure CML (carboxy-methyllysine), another potential cardiovascular risk marker.

Synvista Therapeutics is developing oral antioxidant drugs to treat the HDL dysfunction seen in Hp2-2 Diabetes, a disease affecting almost 7 million patients in the United States. The Company is also developing alagebrium, a proposed breaker of advanced glycation endproducts (AGEs) for the treatment of systolic and diastolic heart failure. Diastolic heart failure represents a rapidly growing market of unmet medical need, particularly common among diabetic patients. Alagebrium has demonstrated relevant clinical activity in two Phase 2 clinical trials in heart failure, as well as in animal models of heart failure and nephropathy, among others. Alagebrium has been tested in approximately 1,000 patients in multiple Phase 1 and Phase 2 clinical
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
2. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
3. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
4. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
5. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
6. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
7. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
8. Synvista Therapeutics to be Featured on Wallst.net
9. Synvista Therapeutics to Present at the BIO InvestorForum 2007
10. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
11. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at UBS 2008 Global Life Sciences Conference in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... CO / Rootstown, OH (PRWEB) January 22, 2015 ... detection platform, announced today that it has received AOAC-PTM Certifications ... O45, O1O3, O111, O121, and O145; collectively referred to as ... coli) O157, at 1 colony forming unit (cfu) per 325 ...
(Date:1/22/2015)... Selexis SA, a serial innovation company with ... used for drug discovery to commercial manufacturing, announced today ... Next-Generation Sequencing (NGS) data packages. The NGS analysis ... ensuring the integrity of the gene, validation of the ...
(Date:1/22/2015)... CAMBRIDGE, Mass. , Jan. 22, 2015   GenoSpace , ... suite of tools to enable the broad use of genomic, ... today announced the appointment of Michelle Munson , CEO ... independent director. Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
(Date:12/24/2014)... Texas , Dec. 24, 2014  Vermillion, Inc. ... on gynecologic disease, announced today that the Company ... including Oracle Investment Management, Jack W. Schuler ... Total proceeds were $10.5 million, before offering expenses.  ...
Breaking Biology Technology:Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2GenoSpace Expands Board with Appointment of Michelle Munson 2Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... SAN FRANCISCO, Calif., June 19 Sunesis,Pharmaceuticals, Inc. (Nasdaq: ... Vice President, Corporate Development and Finance, will,provide a corporate ... 2:00 p.m. Eastern Time on June 26, 2008 at ... may access a webcast of the presentation by visiting,the ...
... Commonwealth of Dominica, June 19 Neuftec,Limited, the ... technology, which recently issued a claim against Oxonica ... for infringement of its,European Patent in the High ... in Oxonica,s AGM Statement issued by Dr Matthews,(CEO) ...
... technique that uses lasers and plastic beads to create ... of microchips. , The method, which creates lines ... human hair, may enable the creation of biological computers ... communications, computing and sensor technologies. , The technique, ...
Cached Biology Technology:Neuftec Responds to a Fundamental Inaccuracy in Oxonica PLC's Regulatory Announcement 2Trap and zap: Harnessing the power of light to pattern surfaces on the nanoscale 2Trap and zap: Harnessing the power of light to pattern surfaces on the nanoscale 3
(Date:1/22/2015)... 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ... on the recent success of the Wocket™ smart wallet at CES 2015 ... wallet was named as one of the "11 Hot Products at CES" ... Launched At CES So Far" by Newseveryday.com and "The top 10 gadgets ...
(Date:1/22/2015)... , Europe,s most prestigious innovation prize ... present a video retrospective of the most exciting and innovative nominations  ... and Sophie Wilson   A different theme ... Starting on 22 January 2015 on   http://www.epo.org/european-inventor   ...
(Date:1/22/2015)... Infinisource has launched its new NXG series of time clocks ... a higher standard for collecting attendance and labor data and ... installation, touch screen interface and seamless connection to cloud-based iSolved, ... solution for the small to mid-size employer. The ...
Breaking Biology News(10 mins):CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3Infinisource's NXG series sets new time clock standard 2
... increase the likelihood of immune complications following bone marrow ... November 22 advance online issue of Nature Genetics ... the donor,s genome but present in the recipient,s, transplants ... known as graft-versus-host disease, in which immune cells from ...
... and technological frontiers. The National Science Foundation has recently ... diverse efforts of the following investigators under the American ... researchers have been awarded grants for investigation of solar ... enhance the capabilities of NJIT,s Big Bear Solar Observatory ...
... to contribute their abstracts to the World Congress on ... meeting devoted to all aspects of osteoporosis and osteoarthritis ... in Florence, Italy from May 5-8, 2010. Beginning ... The submission deadline is February 4, ...
Cached Biology News:Gene mismatch influences success of bone marrow transplants 2Gene mismatch influences success of bone marrow transplants 3Gene mismatch influences success of bone marrow transplants 4NJIT receives NSF funding to improve Big Bear Telescope, study solar energy 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 3
Human Serpin B5/Maspin Affinity Purified Polyclonal Ab...
geminin, DNA replication inhibitor...
One-step, microplate or cuvet, colorimetric, linear detection range 0.1 mg/dL to 100 mg/dL. Procedure: 20 min....
biotin-4-fluorescein...
Biology Products: